Article Text

Download PDFPDF
Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures
  1. Philipp Schulz1,
  2. Ashley Wiginton2 and
  3. Amar Mahgoub2
  1. 1Internal Medicine, Texas Tech University Health Sciences Center School of Medicine Permian Basin, Odessa, Texas, USA
  2. 2Transplant Hepatology and Gastroenterology, Baylor University Medical Center, Dallas, Texas, USA
  1. Correspondence to Dr Philipp Schulz; schulz.philipp90{at}


This case represents the first report of a detected hepatitis C virus (HCV) infection following a pancreas transplantation that failed two different sofosbuvir (SOF)-based treatments. We present the case of a woman in her 30s with a history of kidney transplantation, who developed viremic symptoms 3 months after pancreas transplantation and with two subsequent negative HCV antibody tests. Further work-up revealed a positive HCV RNA test (genotype 1A, treatment naive). Two different direct-acting antiviral agents regimes with SOF failed in our case, and the patient achieved a sustained virological response with a 16-week course of glecaprevir/pibrentasvir.

  • Transplantation
  • Hepatitis C

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors PS: conceptualised and designed the study; acquired, analysed and interpreted study data; and drafted and revised the manuscript. AM: analysed and interpreted study data and critically revised the manuscript. AW: gained informed consent from the patient and was involved in the direct patient care.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.